Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing the Synergy Between Behavioural Activation Therapy and Esketamine for Resistant Depression

NCT06431386 is registered in ClinicalTrials.gov with The Royal's Institute of Mental Health Research as lead sponsor.

NCT NCT06431386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06431386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing the Synergy Between Behavioural Activation Therapy and Esketamine for Resistant Depression
Lead sponsor
The Royal's Institute of Mental Health Research
Phase
Not applicable
Overall status
Terminated
Start date
June 11, 2024
Completion date
September 17, 2025
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, depressive disorder, major, depressive disorder, treatment-resistant